Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
Status:
Withdrawn
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
To compare two commonly used MS medications, IFN β-1a subcutaneous three times per week
(Rebif) and oral twice daily dimethyl fumarate (Tecfidera), on mean number of new or
enlarging T2 lesions at 6 months in adults with relapsing-remitting multiple sclerosis who
are prescribed these medications and receive a 6 month MRI scan as standard of care.